Cefdinir
| Clinical data | |
|---|---|
| Pronunciation | SEF-di-nir |
| Trade names | Cefzon, Omnicef, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a698001 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 16% to 21% (dose-dependent) |
| Protein binding | 60% to 70% |
| Metabolism | Negligible |
| Elimination half-life | 1.7 ± 0.6 hours |
| Excretion | Kidney |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.171.145 |
| Chemical and physical data | |
| Formula | C14H13N5O5S2 |
| Molar mass | 395.41 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 170 °C (338 °F) (dec.) |
SMILES
| |
InChI
| |
| (verify) | |
Cefdinir, sold under the brand name Omnicef among others, is an antibiotic used to treat bacterial infections including bacterial pneumonia, other respiratory tract infections, otitis media, strep throat, and cellulitis. It may also be used as an alternative antibiotic for those with a severe penicillin allergy. It is taken by mouth.[1][2][3]
Common side effects include diarrhea, nausea, and a skin rash.[1] Serious side effects may include Clostridioides difficile infection, anaphylaxis, and Stevens–Johnson syndrome.[1] Use in pregnancy and breastfeeding is believed to be safe but has not been well studied.[4]
It is a third-generation cephalosporin antibiotic and works by interfering with a bacteria's ability to make a cell wall, resulting in its death.[1]
- ^ a b c d "Cefdinir Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 23 March 2019.
- ^ "Cefdinir (oral route)". Mayo Clinic. Retrieved 26 May 2025.
- ^ "Cefdinir: MedlinePlus Drug Information". medlineplus.gov. Retrieved 26 May 2025.
- ^ "Cefdinir Use During Pregnancy". Drugs.com. Retrieved 3 March 2019.